Skip to main content

Table 2 Univariate analysis of prognostic factors for progression-free survival

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Variables

HR (95% CI)

P value

Gender

 Male

Reference

 

 Female

1.634(0.793,3.368)

0.183

ECOG performance

 1

Reference

 

 0

0.846(0.485,1.474)

0.555

Hepatitis

 Hepatitis B

Reference

 

 Other

0.845(0.431,1.656)

0.624

Child–Pugh score

 B

Reference

 

 A

1.715(0.415,7.088)

0.456

Age (years)

0.987(0.961,1.015)

0.358

AST (µmol/L)

1.004 (0.997,1.010)

0.262

ALT (µmol/L)

1.006 (0.992, 1.020)

0.414

PLR

1.002(0.999, 1.006)

0.244

NLR

0.795(0.653, 0.969)

0.023

Albumin (g/L)

1.004 (0.913, 1.104)

0.934

TB (µmol/L)

0.973(0.933,1.015)

0.200

PT (s)

1.001(0.807,1.241)

0.991

Tumor size

0.979 (0.862, 1.112)

0.744

BCLC stage

 C

Reference

 

 B

0.557(0.299, 1.037)

0.065

Tumor number

  = 1

Reference

 

  ≥ 2

0.551 (0.299, 1.017)

0.057

α-Fetoprotein level

  ≥ 400 ng/mL

Reference

 

  < 400 ng/mL

1.168 (0.643, 2.121)

0.610

Treatment method

 TACE-alone

Reference

 

 TACE-camrelizumab

1.206(0.599,2.428)

0.600

  1. Note. HR: Hazard ratio; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; TB: Total bilirubin; PT: Prothrombin time; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio